TRAF6 regulates the effects of polarized maturation of tolerability: Marrow‑derived dendritic cells on collagen‑induced arthritis in mice

Introduction

Rheumatoid arthritis (RA) is associated with T cells and immune cell activation, resulting in joint synovitis. Dendritic cells (DCs) are antigen-presenting cells (APCs) specialized in activating T cells with a positive or negative immune response (1,2). DCs play different functional roles at different maturation states. The antigen-presenting ability of mature DCs promotes immune response by the activation of T cells, while that of immature DCs inhibits the activation of T lymphocytes and activates regulatory T cells (Tregs) (3,4). Immature DCs mediate immune tolerance. Tumor necrosis factor receptor-associated factor 6 (TRAF6) activates TAK1 and NF-κB molecules in Toll-like receptor (TLR)-signaling pathways, which enter into the nucleus (5,6). To the best of our knowledge, no report has yet established any association between TRAF6 and DC maturation, and that TRAF6 promotes a DC-mediated immune response. We induced DCs at different maturation states to detect TRAF6 expression by cytokines to analyze the correlation between TRAF6 and DCs. Thus, this experiment mainly studied the effect of TRAF6-specific expression on immature dendritic cell (iDC) maturation and the immune tolerance re-establishment.

Materials and methods

The study was approved by the Ethics Committee of the Guilin Medical University.

Preparation of the collagen-induced arthritis (CIA) animal model

Fifty 8-week-old male C57 mice, weighing approximately 30 g were obtained from the Guilin Medical College Experimental Animal Center. Prior to the experiment, chicken type II collagen (including acetic acid with a concentration of 2 mg/ml) was added slowly to the same volume of complete Freund's adjuvant (CFA), prepared in sufficient emulsification on ice and the final concentration of the mixture was 1 mg/ml. The C57 mice were immunized intradermally twice at the base of the tail and the back at intervals of 4 weeks, while the normal controls were intragastrically administered with saline. The mice were monitored daily for swelling of limbs for at least 28 days and serum samples were collected at day 7 or 14 after boosting immunity. After the building model was established, the mice that scored >6 points in the arthritis index (AI) scoring were used for further testing.

Generation and activation of bone marrow-derived DCs (BMDCs)

BMDCs were obtained from the femurs and tibias of the CIA mice, and the red cells were treated with a lysis buffer solution (4.15 g of ammonium chloride per 500 ml of 0.01 M Tris-HCl buffer). The cells were then washed and cultured in culture flasks at 1×109 cells/ml in a complete RPMI-1640 culture medium supplemented with 10% fetal bovine serum (FBS), IL-4 (5,000 U/ml), and GM-CSF (1,000 U/ml). The culture medium was changed on culture days 3 and 5. New medium and cytokines (GM-CSF and IL-4) were added after rinsing the non-adherent cells. On day 6, any loosely adherent clustered cells were defined as immature BMDCs.

Different maturation stimuli on DCs

DCs were harvested on culture day 6. Briefly, BMDCs (1×106/well) were seeded in 24-well plates in 1 ml of culture medium and treated with recombinant granulocyte-macrophage colony-stimulating factor (rmGM-CSF). IDCs were induced to DCs at different maturation states according to different methods. The cells were divided into four groups, as follows: group A, the control group was treated with rmGM-CSF and recombinant interleukin-4 (rmIL-4) (rmGM-CSF, rmIL-4 group). Group B, this group was treated with TNF-α (1×106 U/l) (TNF-α group). Group C, this group was treated with LPS (1 mg/l) (LPS group). Group D, this group was treated with rmGM-CSF (10 ng/ml), FK506 (10 ng/ml), and LPS (1 mg/l) (FK506 group). Each group was then incubated for 24 h.

Flow cytometric analysis of DC phenotypes

The cells were collected on day 7, and washed with PBS. The cells were stained with fluorescence-labeled antibodies (anti-mouse CD11c-APC, CD80-PE, CD86-PE, and MHC-II-PE) for 30 min on ice, washed with FBS, and analyzed via flow cytometry. Data analyses were performed using BD FACSDiva software (Becton-Dickinson, Mountain View, CA, USA). The initially gated cells were further analyzed for CD11c, CD80, CD86, and MHC-II expression.

Different levels of IL-12 secretion by enzyme-linked immunosorbent assay (ELISA)

A commercial ELISA kit (PBL Biomedical Laboratories, Piscataway, NJ, USA) was used to measure the serum levels of IL-12 secretion according to the manufacturer's instructions.

Reverse transcription-polymerase chain reaction (RT-PCR)

Cells in the logarithmic phase were collected, and then total RNA was extracted from the cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA was quantified using UV absorbance at 260 and 280 nm (A260/280) by NanoDrop 2000 spectrophotometry (Thermo Fisher Scientific, Waltham, MA, USA). RNA was reverse-transcribed using the BU-Script RT kit (Tiangen Biotech Co., Ltd., Beijing, China) according to the manufacturer's instructions. Primers TRAF6-F (5′-GCC GAA ATG GAA GCA CAG-3′) and TRAF6-R (5′-GGG CTA TGG ATG ACA ACA GG-3′) were used in conventional PCR detection (Tiangen Biotech Co., Ltd.). The procedures were performed as described elsewhere (7).

Expression of TRAF6 protein by western blot analysis

Total protein from cell lysates was separated by SDS-PAGE and transferred to a nitrocellulose membrane, which was incubated with the 1:200 diluted specific primary antibodies TRAF6 (ab33915, rabbit polyclonal antibody; Abcam, Cambridge, UK) overnight at 4°C. After incubation with the 1:1,000 diluted HRP-labeled secondary antibody (horseradish peroxidase conjugated goat anti-rabbit immunoglobulin; Abcam) at room temperature for 1 h, the membranes were developed with enhanced chemiluminescence (ECL) detection system (Gel Logic 2200 PRO; Kodak, Tokyo, Japan).

Statistical analysis

SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA) was used to conduct analyses. Data were presented as means ± SD to indicate single factor variance. Comparisons were made using one-way ANOVA. The differences were considered significant when P<0.05.

Results

CIA induction

A boost injection of equal collagen-IFA suspension was given in the same manner on day 21. The experimental group with 50 C57 mice had 40 mice successfully modeling CIA (4/5). Clinical symptoms of CIA started to occur around day 28 after the primary immunization, including joint swelling and joint deformity (Fig. 1).

Figure 1. Immunization on day 28: The paws of the CIA mice appeared red and swollen. CIA, collagen-induced arthritis.

DC cultures

Bone marrow cells of the C57 mice were induced to differentiate the BMDCs by cytokines rmGM-CSF and rmIL-4. Flow cytometric identification of CD11c DCs was >70%.

Changes in the expression of DC maturation

To analyze the expression of the co-stimulatory molecules (i.e., CD80, CD86, and MHC-II) from differentially matured DCs in the experimental groups, the results show that there is an increasing trend in the expression of the co-stimulatory molecules among the four groups (Table I), and the difference was statistically significant (P<0.05). The expression of CD86 in group D was higher than that in the other three groups (mean 69.55±2.26). The results suggested that group D demonstrated highly increased levels of DC maturation.

Table I. Expression of the co-stimulatory molecules in the four groups of DCs.

Table I.

Expression of the co-stimulatory molecules in the four groups of DCs.

Group	CD80	CD86	MHC-II
A	9.06±0.58	12.32±0.62	8.36±0.62
B	11.06±0.68	18.65±0.83	9.23±0.61
C	14.67±0.74	30.37±1.37	14.28±0.60
D	19.01±0.92	69.55±0.96	18.19±0.96

[i] The difference among the four groups was statistically significant (P<0.05). DCs, dendritic cells.

IL-12 expression by DCs at different matured states

The supernatants from the four groups were harvested and analyzed by ELISA. The concentration of each group was calculated from OD readings using a standard curve. The values were as follows: group A, 1,623.35±83.32 pg/ml; group B, 2,486.14±65.26 pg/ml; group C, 3,742.58±87.16 pg/ml; and group D, 10,620.73±276.73 pg/ml (Fig. 2). There was a significant difference in each group (P<0.05).

Figure 2. Expression of IL-12 in the four groups of DCs. DCs, dendritic cells.

mRNA-TRAF6 by pulsed-field gel electrophoresis (PFGE)

The expression of mRNA-TRAF6 in group D was superior to that of the three other groups (P<0.01). The level of mRNA-TRAF6 expression in groups B and C was higher than that in the control group (P<0.01). The results were as follows: group A, 0.046±0.007; group B, 0.063±0.006; group C, 0.062±0.006; and group D, 0.151±0.08 (Fig. 3).

Figure 3. Expression of RNA-TRAF6 in the groups of DCs. TRAF6, tumor necrosis factor receptor-associated factor 6; DCs, dendritic cells.

Expression of protein TRAF6 in DCs

The expression of protein TRAF6 in group D was superior to the three other groups by inducing DC at different maturation states. The differences were statistically significant (P<0.01). The difference between groups B and C, and group A was statistically significant (P<0.01) (Fig. 4). The results in the four groups were as follows: group A, 0.49±0.006; group B, 0.65±0.005; group C, 0.75±0.005; and group D, 1.15±0.003.

Figure 4. Expression of RNA-TRAF6 in the groups of DCs. TRAF6, tumor necrosis factor receptor-associated factor 6; DCs, dendritic cells.

Discussion

RA is a systemic, inflammatory, autoimmune disorder. However, the exact mechanism has yet to be fully clarified. Most scholars believe that the pathogenesis of RA may be caused by chronic inflammation of synovial tissue. During the onset of RA, an acute inflammation of the synovial lining (synovitis) leads to an extensive expansion of the corresponding cells (i.e., pannus formation and inflammatory cytokines), massive infiltration of leukocytes of the innate immune system (i.e., T and B cells, plasmocytes, and macrophages), and synovial fibroblast proliferation (8–10). The latter are regarded as effector cells responsible for cartilage and bone destruction in RA. Then, RA leads to deformity and evenutally to significant functional decline (11,12).

Following in-depth study of the pathogenesis of RA, most scholars agree that the abnormalities of autoreactive T cells induced by antigen-presenting cells (APCs) are the central link in the pathogenesis of RA (13–15). DCs are the most powerful APCs and play an important role in the abnormal activation of T cells and the occurrence and development of RA. DCs present a two-way immune regulation: i) Ability to capture, process, and present exogenous antigens leading to T-cell differentiation and immune response; and ⅱ) ability of DC to trigger an effective T-cell response and production of self- and foreign antigens. Thus, DCs are important in sustaining the central and peripheral immune tolerance (16–19).

Recent studies found that TLRs are crucial cellular sentinels used to detect ‘danger’ signals released in DCs and may be important initiators of DC maturation and activation. TRAF6 is a key to TLR activation and intersecting signaling pathways activated the NF-κB and mitogen-activated protein kinase pathways. TRAF6 assists in the maturity of DC-mediated signal transduction and is a key to DC formation, activation, and maturation (20–22). Thus, to explore specific interventions of TRAF6 expression is essential, which inhibits DC maturation, reconstructs RA immune tolerance, and plays a therapeutic role (23,24).

We found that DCs derived from mouse bone marrow and different methods stimulated differentiation and maturation of DCs. Expression of co-stimulatory molecules (i.e., CD80 and CD86) increased in the mature DC, enhanced the ability of antigen presentation, and decreased antigen uptake. The highest maturity degree of DCs is CD86 expression, while in the experiments IL-12 is produced mainly by DCs, macrophages, and B lymphocytes. The increased secretion of IL-12 into the supernatants was altered with the increase of maturity degree, which is consistent with previous literature (25,26). The present findings have shown that the TRAF6 gene and protein expression were correlated with DC maturity, which showed an increasing trend. Among the most obvious was the cocktail method. Some studies found that under appropriate stimulation conditions, DCs with a TRAF6 gene defect failed to upregulate co-stimulatory molecules (i.e., CD80 and CD86), MHC, and release of pro-inflammatory cytokines and did not activate T cell-mediated immune responses (27). Those results are consistent with our findings, which show that TRAF6 plays an important role in DC differentiation and maturation.

Previous results showed that no or a low expression of co-stimulatory molecules was detected in immature DCs by mediating immune clearance, immune incompetent, and Treg cell induction. Thus, the iDCs induced peripheral immune tolerance, maintained immune balance, and inhibited autoimmunity disease. The study found that there was an increasing trend for DCs in different maturation states with increasing TRAF6 expression Thus, we inhibited the expression of TRAF6 in DCs, which reduced the Toll-TRAF6 NF-κB signaling pathway, maintained DCs in an immature state, and decreased the release of pro-inflammatory cytokines (i.e., IL-1, IL-6, IL-12, and TNF-α). It is expected that the immune tolerance may be re-established through the intervention of TRAF6 expression. This study has clearly shown that TRAF6 regulates the differentiation and maturation of DCs in animal experiments. Thus, TRAF6 should be evaluated as a potential target for clinical therapy.

Acknowledgements

Te present study was supported by grants from the Chinese National Natural Science Foundation (no. 81360462) and the Guangxi Natural Science Foundation (no. 2013GXNSFAA019111).

References